Vaxart, Inc. (VXRT) Stock

Vaxart, Inc., a clinical-stage biotechnology company based in South San Francisco, California, specializes in pioneering the discovery and development of oral recombinant protein vaccines utilizing its innovative proprietary platform. Central to its pipeline is a norovirus vaccine, currently undergoing Phase Ib clinical trials. This oral tablet vaccine targets both the GI.1 and GII.4 strains of norovirus, aiming to provide a convenient and effective solution against this prevalent gastrointestinal infection.

In addition to its norovirus vaccine, Vaxart, Inc. is advancing several other promising candidates. These include a seasonal influenza vaccine, currently in Phase II clinical trials for treating H1 influenza infections, and a respiratory syncytial virus vaccine. Notably, the company is also actively developing a coronavirus vaccine, which is undergoing Phase II clinical trials for combatting SARS-CoV-2 infections. Beyond infectious diseases, Vaxart, Inc. is exploring therapeutic vaccines designed to address cervical cancer and dysplasia caused by human papillomavirus, underscoring its commitment to tackling significant health challenges with innovative oral vaccine solutions.

Established as a forward-thinking entity in 2004, Vaxart, Inc. continues to drive advancements in biotechnology with its focus on oral vaccines. By leveraging its proprietary technology, the company seeks to revolutionize vaccine delivery, potentially offering easier administration and broader accessibility compared to traditional injectable vaccines. With a robust pipeline and headquarters situated in the biotech hub of South San Francisco, Vaxart, Inc. remains dedicated to reshaping the landscape of preventive and therapeutic vaccines for global health.